These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 32799659)
21. Identification of S100A8 and S100A9 as negative regulators for lymph node metastasis of gastric adenocarcinoma. Choi JH; Shin NR; Moon HJ; Kwon CH; Kim GH; Song GA; Jeon TY; Kim DH; Kim DH; Park DY Histol Histopathol; 2012 Nov; 27(11):1439-48. PubMed ID: 23018243 [TBL] [Abstract][Full Text] [Related]
22. Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients. Haas CJ; Wagner T; Wawroschek F; Arnholdt H Pathol Res Pract; 2005; 200(11-12):763-70. PubMed ID: 15792118 [TBL] [Abstract][Full Text] [Related]
23. Over-expression of a poor prognostic marker in prostate cancer: AQP5 promotes cells growth and local invasion. Li J; Wang Z; Chong T; Chen H; Li H; Li G; Zhai X; Li Y World J Surg Oncol; 2014 Sep; 12():284. PubMed ID: 25217331 [TBL] [Abstract][Full Text] [Related]
24. D-PCa-2: a novel transcript highly overexpressed in human prostate and prostate cancer. Weigle B; Kiessling A; Ebner R; Fuessel S; Temme A; Meye A; Schmitz M; Rieger MA; Ockert D; Wirth MP; Rieber EP Int J Cancer; 2004 May; 109(6):882-92. PubMed ID: 15027122 [TBL] [Abstract][Full Text] [Related]
25. Androgen receptor status of lymph node metastases from prostate cancer. Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A Prostate; 1996 Feb; 28(2):129-35. PubMed ID: 8604394 [TBL] [Abstract][Full Text] [Related]
26. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839 [TBL] [Abstract][Full Text] [Related]
27. XPNPEP2 is associated with lymph node metastasis in prostate cancer patients. Li F; Dai Y; Xu H; Huang K; Zhou Y; Luo D; Ma D; Xi L; Lv M; Ma X Sci Rep; 2019 Jul; 9(1):10078. PubMed ID: 31296901 [TBL] [Abstract][Full Text] [Related]
28. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Chen G; Sircar K; Aprikian A; Potti A; Goltzman D; Rabbani SA Cancer; 2006 Jul; 107(2):289-98. PubMed ID: 16752412 [TBL] [Abstract][Full Text] [Related]
29. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer. Ferrari AC; Stone NN; Eyler JN; Gao M; Mandeli J; Unger P; Gallagher RE; Stock R J Natl Cancer Inst; 1997 Oct; 89(20):1498-504. PubMed ID: 9337346 [TBL] [Abstract][Full Text] [Related]
30. Development and validation of hub genes for lymph node metastasis in patients with prostate cancer. Xu N; Chen SH; Lin TT; Cai H; Ke ZB; Dong RN; Huang P; Li XD; Chen YH; Zheng QS J Cell Mol Med; 2020 Apr; 24(8):4402-4414. PubMed ID: 32130760 [TBL] [Abstract][Full Text] [Related]
31. A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Xi L; Coello MC; Litle VR; Raja S; Gooding WE; Yousem SA; El-Hefnawy T; Landreneau RJ; Luketich JD; Godfrey TE Clin Cancer Res; 2006 Apr; 12(8):2484-91. PubMed ID: 16638856 [TBL] [Abstract][Full Text] [Related]
32. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Lunger L; Retz M; Bandur M; Souchay M; Vitzthum E; Jäger M; Weirich G; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Koll F; Gschwend JE; Nawroth R; Heck MM Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):362-369. PubMed ID: 32978525 [TBL] [Abstract][Full Text] [Related]
33. Cytokeratin 20 and guanylyl cyclase C mRNA is largely present in lymph node and liver specimens of colorectal cancer patients. Conzelmann M; Dieterle CP; Linnemann U; Berger MR Int J Cancer; 2003 Nov; 107(4):617-28. PubMed ID: 14520701 [TBL] [Abstract][Full Text] [Related]
34. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? Bader P; Burkhard FC; Markwalder R; Studer UE J Urol; 2002 Aug; 168(2):514-8; discussion 518. PubMed ID: 12131300 [TBL] [Abstract][Full Text] [Related]
35. Development and internal validation of a novel model and markers to identify the candidates for lymph node metastasis in patients with prostate cancer. Cao HM; Wan Z; Wu Y; Wang HY; Guan C Medicine (Baltimore); 2019 Jul; 98(30):e16534. PubMed ID: 31348270 [TBL] [Abstract][Full Text] [Related]